Summary
A recent survey of over 1,700 patient groups around the world has revealed the true toll the COVID-19 pandemic has had on patient communities, with many individuals feeling more vulnerable, confused and uncertain about the consistency and continuity of their care.
Now, more than ever, the life sciences industry has a responsibility to listen to the unique and changing needs of patients. They must continue to work with patient organisations on their vital work to safeguard continued access to treatment and to understand their need for holistic support ‘beyond the pill’.
Dr Berkeley Phillips, Country Medical Director of Pfizer UK, explains in this article how Pfizer continues to partner with patient organisations across a broad spectrum of conditions from cancer to rare diseases, ensuring patients feel equipped, informed and empowered despite the uncertainty.
0 Comments
Recommended Comments
There are no comments to display.
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now